Highlights
- A large-scale retrospective study of the NIH ‘All of Us’ Research Program reveals that patients with Fuchs’ Endothelial Corneal Dystrophy (FECD) have a significantly higher burden of cardiometabolic diseases compared to matched controls.
- Key comorbidities identified include Type 2 Diabetes Mellitus (T2DM), hypertension, hyperlipidemia, and coronary artery disease.
- The findings suggest a shared pathophysiology involving oxidative stress, mitochondrial dysfunction, and chronic systemic inflammation.
- Clinicians should consider the systemic health profile of FECD patients, particularly as metabolic health may influence corneal surgical outcomes and disease progression.
Background
Fuchs’ Endothelial Corneal Dystrophy (FECD) is a progressive, bilateral corneal disease characterized by the gradual loss of corneal endothelial cells and the formation of extracellular collagenous deposits known as ‘guttata.’ As the most common cause of corneal endothelial failure, FECD frequently leads to corneal edema, painful bullae, and significant visual impairment, often necessitating surgical intervention via endothelial keratoplasty (e.g., DMEK or DSAEK). Historically, FECD has been viewed as a largely isolated ocular pathology, primarily driven by genetic predispositions—most notably the CTG18.1 expansion in the TCF4 gene—and localized environmental stressors.
However, emerging evidence has begun to challenge this localized paradigm. The corneal endothelium is a metabolically high-demand tissue, relying heavily on mitochondrial function and sodium-potassium ATPase pumps to maintain corneal deturgescence. Given that cardiometabolic diseases also share roots in mitochondrial dysfunction and oxidative damage, researchers have hypothesized a potential link between systemic metabolic health and the integrity of the corneal endothelium. Despite these hypotheses, clinical evidence linking FECD to systemic metabolic profiles has been sparse until recently.
Key Content
The All of Us Research Program: Study Design and Population
A pivotal study by Mihalache et al. (2026), published in Ophthalmology, utilized data from the National Institutes of Health (NIH) All of Us Research Program to investigate the association between FECD and cardiometabolic comorbidities. This retrospective cohort study included 548 individuals diagnosed with FECD and 5,480 controls matched by age, sex, and ethnicity (1:10 ratio). The use of the All of Us dataset is particularly significant due to its emphasis on diverse populations and longitudinal electronic health record (EHR) integration, providing a more comprehensive view of patient health than traditional clinical trials.
Analysis of Cardiometabolic Comorbidities
The primary findings of the synthesis indicate a stark contrast in the cardiometabolic profiles of FECD patients versus their healthy counterparts. The researchers observed a significantly higher prevalence of several metabolic syndrome components in the FECD group:
- Hypertension: FECD patients exhibited a higher frequency of hypertension, with adjusted odds ratios suggesting a robust association even after correcting for demographic variables.
- Diabetes Mellitus: Both Type 1 and Type 2 diabetes were more prevalent in the FECD cohort. Type 2 diabetes (T2DM), in particular, showed a strong correlation, possibly due to the systemic glycation effects that mirror the oxidative stress seen in corneal endothelial guttata.
- Hyperlipidemia and Obesity: Elevated Body Mass Index (BMI) and dyslipidemia were consistently more frequent in patients with endothelial dystrophy, further supporting the metabolic link.
- Coronary Artery Disease (CAD): Perhaps most concerningly, a higher burden of cardiovascular events and CAD was documented in the FECD cohort, pointing toward a possible systemic vascular vulnerability.
Mechanistic Insights: Shared Biological Pathways
The association between FECD and cardiometabolic disease is likely rooted in several shared biological mechanisms. A primary suspect is **oxidative stress**. The corneal endothelium is constantly exposed to UV light and high metabolic demands, making it a hotspot for reactive oxygen species (ROS). Similarly, the vascular endothelium in cardiometabolic disease suffers from ROS-induced damage.
Furthermore, **mitochondrial dysfunction** is a hallmark of both FECD and metabolic syndrome. In FECD, mitochondrial DNA damage and reduced ATP production lead to endothelial cell apoptosis. In systemic diabetes and heart disease, similar mitochondrial failures drive insulin resistance and atherosclerosis. The TCF4 gene expansion, while specific to the cornea in its phenotypic expression of guttata, may also interact with systemic metabolic pathways that govern how cells respond to stress and inflammation.
Chronological Progression of Evidence
Early studies in the 2000s and 2010s (e.g., Jurkunas et al.) focused heavily on the TCF4 mutation and the unfolded protein response (UPR) within corneal cells. By 2020, research began to shift toward lifestyle factors, with smaller studies suggesting that smoking and higher BMI were associated with more severe FECD phenotypes. The 2026 Mihalache study represents a culmination of this shift, moving from small, localized cohorts to a massive, multi-center registry that confirms FECD as a potential biomarker for broader metabolic dysfunction.
Expert Commentary
The findings by Mihalache et al. provide a crucial update to our understanding of corneal dystrophies. For years, ophthalmologists have focused almost exclusively on the slit-lamp examination of the cornea, but these data suggest we should be looking at the patient as a whole.
One critical consideration is the direction of causality. Does the systemic metabolic environment accelerate the decay of the corneal endothelium, or do shared genetic risk factors predispose individuals to both? Given the metabolic sensitivity of endothelial cells, it is highly probable that systemic hyperglycemia and hypertension create a ‘second hit’ on an already genetically vulnerable cornea.
From a clinical standpoint, this research has two immediate applications. First, FECD patients should be screened for underlying cardiometabolic risk factors if they are not already being managed by a primary care physician. Second, when preparing for endothelial keratoplasty, surgeons should be aware that a patient’s metabolic status (e.g., uncontrolled diabetes) may negatively impact the survival of the donor graft, as systemic inflammation can influence the ocular microenvironment post-surgery.
Limitations of the current evidence include the retrospective nature of registry data, which may involve coding biases, and the lack of granular data on the severity of the CTG18.1 expansion in all patients. Future prospective studies are needed to determine if aggressive management of metabolic syndrome can slow the progression of corneal guttata.
Conclusion
Fuchs’ Endothelial Corneal Dystrophy is no longer an isolated ocular condition. The significant association with hypertension, diabetes, and coronary artery disease underscores a systemic cardiometabolic burden that clinicians must address. By recognizing these links, healthcare providers can move toward a more integrated approach to care—one that preserves both the vision and the long-term systemic health of patients with FECD. Future research should investigate whether metabolic interventions, such as antioxidants or glycemic control, can serve as adjunctive therapies to delay the need for corneal transplantation.
References
- Mihalache A, Huang RS, Popovic MM, Chan CC. Fuchs’ Endothelial Corneal Dystrophy and Cardiometabolic Comorbidities. Ophthalmology. 2026-03-04. PMID: 41791678.
- Sarnicola C, Farooq AV, Yi K, et al. Fuchs’ endothelial corneal dystrophy: A review. Surv Ophthalmol. 2019;64(1):1-29. PMID: 30025912.
- Jurkunas UV. Fuchs Endothelial Corneal Dystrophy: The Path of Oxidative Stress. Semin Ophthalmol. 2010;25(5-6):262-269. PMID: 21091065.
- Ong HS, Ang M, Mehta JS. Endothelial Diseases of the Cornea: Emerging Therapies for Endothelial Failure. Prog Retin Eye Res. 2021;82:100904. PMID: 33068735.
